Literature DB >> 11429482

Signal transduction pathways in sarcoma as targets for therapeutic intervention.

D A Tuveson1, J A Fletcher.   

Abstract

Investigations into the molecular alterations in sarcomas have made substantial progress during the past decade. Classical linkage analysis and the direct sequencing of chromosomal translocation fusions have identified candidate genes in many different sarcomas. A large group of these genes participate in signal transduction pathways and represent potential sites of disease intervention with targeted therapies. This review will discuss five types of sarcoma that display aberrant tyrosine kinase pathway signaling: gastrointestinal stromal tumor, inflammatory myofibroblastic tumor, congenital fibrosarcoma and mesoblastic nephroma, dermatofibrosarcoma protuberans, and desmoplastic small round cell tumor; one sarcoma predisposition syndrome with specific dysregulation of the ras pathway--neurofibromatosis--will also be discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11429482     DOI: 10.1097/00001622-200107000-00007

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  5 in total

Review 1.  Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas.

Authors:  Blanca Homet Moreno; Elena Garralda Cabanas; Ricardo Hitt
Journal:  Clin Transl Oncol       Date:  2010-07       Impact factor: 3.405

2.  Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.

Authors:  Suzanne George; Priscilla Merriam; Robert G Maki; Annick D Van den Abbeele; Jeffrey T Yap; Timothy Akhurst; David C Harmon; Gauri Bhuchar; Margaret M O'Mara; David R D'Adamo; Jeffrey Morgan; Gary K Schwartz; Andrew J Wagner; James E Butrynski; George D Demetri; Mary L Keohan
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

Review 3.  Molecular genetics of pediatric soft tissue tumors: clinical application.

Authors:  Chung-Che Chang; Vinod B Shidham
Journal:  J Mol Diagn       Date:  2003-08       Impact factor: 5.568

4.  Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and casein kinase II inhibition as a potential treatment option.

Authors:  Stefan M Willems; Yvonne M Schrage; Inge H Briaire-de Bruijn; Karoly Szuhai; Pancras C W Hogendoorn; Judith V M G Bovée
Journal:  Mol Cancer       Date:  2010-09-23       Impact factor: 27.401

5.  Management of advanced adult soft tissue sarcoma.

Authors:  Vivien H C Bramwell
Journal:  Sarcoma       Date:  2003
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.